Research programme: drug discovery - Merck Serono/Swiss Federal Institute of Technology Lausanne

Drug Profile

Research programme: drug discovery - Merck Serono/Swiss Federal Institute of Technology Lausanne

Latest Information Update: 09 Oct 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Merck Serono; Swiss Federal Institute of Technology - Lausanne
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Neurological disorders

Most Recent Events

  • 09 Oct 2012 No development reported for Cancer in Switzerland (unspecified route)
  • 09 Oct 2012 No development reported for Neurological disorders in Switzerland (unspecified route)
  • 09 Apr 2009 Research is ongoing in Switzerland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top